omarigliptin omarigliptin omarigliptin (mk-3102) is a potent, long-acting oral antidiabetic drug of the dpp-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by merck & co. it inhibits dpp-4 to increase incretin levels (glp-1 and gip), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels. omarigliptinclinical dataother namesmk-3102routes ofadministrationoralatc codenonelegal statuslegal status developing identifiers iupac name (2r,3s,5r)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolopyrazol-5-yl)oxan-3-amine cas number1226781-44-7pubchem cid46209133chemspider28424182uniicvp59q4je1keggd10317chemblchembl2105762comptox dashboard (epa)dtxsid70153678 echa infocard100.207.924 chemical and physical dataformulac17h20f2n4o3smolar mass398.43 g·mol−13d model (jsmol)interactive image smiles cs(=o)(=o)n1cc2c(n1)cn(c2)3c((oc3)c4cc(ccc4f)f)n inchi inchi=1s/c17h20f2n4o3s/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17h,5-6,8-9,20h2,1h3/t12-,15+,17-/m1/s1key:mkmpwkuahltibj-istrzqftsa-n history marizev (omarigliptin) 25 mg and 12.5 mg tablets were approved by japan's pharmaceuticals and medical devices agency (pmda) on 28th sept 2015. japan was the first country to have approved omarigliptin. however merck has announced that the company will not submit marketing application in the us and europe.